KR101667960B1 - 암 치료에서 이용하기 위한 멀티키나아제 억제제 - Google Patents

암 치료에서 이용하기 위한 멀티키나아제 억제제 Download PDF

Info

Publication number
KR101667960B1
KR101667960B1 KR1020157033387A KR20157033387A KR101667960B1 KR 101667960 B1 KR101667960 B1 KR 101667960B1 KR 1020157033387 A KR1020157033387 A KR 1020157033387A KR 20157033387 A KR20157033387 A KR 20157033387A KR 101667960 B1 KR101667960 B1 KR 101667960B1
Authority
KR
South Korea
Prior art keywords
compound
formula
mmol
compounds
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020157033387A
Other languages
English (en)
Korean (ko)
Other versions
KR20150138417A (ko
Inventor
세르게이 아고울닉
부르스 데코스타
홍 두
이민 지앙
시앙-이 리
겐이치 노모토
존 왕 (위안)
후이밍 장
Original Assignee
에자이 알앤드디 매니지먼트 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에자이 알앤드디 매니지먼트 가부시키가이샤 filed Critical 에자이 알앤드디 매니지먼트 가부시키가이샤
Publication of KR20150138417A publication Critical patent/KR20150138417A/ko
Application granted granted Critical
Publication of KR101667960B1 publication Critical patent/KR101667960B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
KR1020157033387A 2007-07-25 2008-07-25 암 치료에서 이용하기 위한 멀티키나아제 억제제 Active KR101667960B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US95190107P 2007-07-25 2007-07-25
US95190607P 2007-07-25 2007-07-25
US60/951,906 2007-07-25
US60/951,901 2007-07-25
US2919608P 2008-02-15 2008-02-15
US61/029,196 2008-02-15
PCT/US2008/071256 WO2009015368A2 (en) 2007-07-25 2008-07-25 Multikinase inhibitors for use in the treatment of cancer

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020107004170A Division KR101573026B1 (ko) 2007-07-25 2008-07-25 암 치료에서 이용하기 위한 멀티키나아제 억제제

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020167028439A Division KR101721161B1 (ko) 2007-07-25 2008-07-25 암 치료에서 이용하기 위한 멀티키나아제 억제제

Publications (2)

Publication Number Publication Date
KR20150138417A KR20150138417A (ko) 2015-12-09
KR101667960B1 true KR101667960B1 (ko) 2016-10-20

Family

ID=40121184

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020107004170A Active KR101573026B1 (ko) 2007-07-25 2008-07-25 암 치료에서 이용하기 위한 멀티키나아제 억제제
KR1020167028439A Active KR101721161B1 (ko) 2007-07-25 2008-07-25 암 치료에서 이용하기 위한 멀티키나아제 억제제
KR1020157033387A Active KR101667960B1 (ko) 2007-07-25 2008-07-25 암 치료에서 이용하기 위한 멀티키나아제 억제제

Family Applications Before (2)

Application Number Title Priority Date Filing Date
KR1020107004170A Active KR101573026B1 (ko) 2007-07-25 2008-07-25 암 치료에서 이용하기 위한 멀티키나아제 억제제
KR1020167028439A Active KR101721161B1 (ko) 2007-07-25 2008-07-25 암 치료에서 이용하기 위한 멀티키나아제 억제제

Country Status (10)

Country Link
US (4) US8609640B2 (enExample)
EP (1) EP2182941B1 (enExample)
JP (2) JP5484327B2 (enExample)
KR (3) KR101573026B1 (enExample)
CN (2) CN101778627B (enExample)
AU (1) AU2008279027B8 (enExample)
CA (1) CA2698271C (enExample)
ES (1) ES2670423T3 (enExample)
IL (2) IL202307A (enExample)
WO (1) WO2009015368A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ535101A (en) * 2002-03-08 2007-07-27 Eisai Co Ltd Macrocyclic compounds useful as pharmaceuticals
EP2182941B1 (en) 2007-07-25 2018-02-28 Eisai R&D Management Co., Ltd. Multikinase inhibitors for use in the treatment of cancer
WO2009058908A2 (en) * 2007-10-29 2009-05-07 Eisai R & D Management Co., Ltd. Methods for prognosing the ability of a zearalenone analog compound to treat cancer
JP5492786B2 (ja) 2007-12-07 2014-05-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 ゼラレノンマクロライドアナログを作製するための中間体および方法
WO2012027716A1 (en) * 2010-08-27 2012-03-01 Collabrx, Inc. Method to treat melanoma in braf inhibitor-resistant subjects
JP6404242B2 (ja) * 2013-06-26 2018-10-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 がんの治療のための併用療法としてのエリブリンおよびレンバチニブの使用
DK3039424T3 (da) 2013-08-28 2020-08-31 Crown Bioscience Inc Taicang Genekspressionssignaturer, der er prædiktive for et individs respons på en multikinaseinhibitor, og fremgangsmåder til anvendelse af disse
WO2015181628A1 (en) * 2014-05-27 2015-12-03 Eisai R&D Management Co., Ltd. Treatment of acute myeloid leukemia with an hck inhibitor
WO2022053130A1 (en) * 2020-09-09 2022-03-17 Sid Alex Group, S.R.O. Antago-mir-155 for treatment of v-src, c-src-tyrosine kinase-induced cancers

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9225396D0 (en) 1992-12-04 1993-01-27 Sandoz Ltd Improvements in or relating to organic compounds
JPH0840893A (ja) 1993-08-31 1996-02-13 Takeda Chem Ind Ltd インターロイキン−１産生抑制剤
DE4420930C2 (de) 1994-06-16 1997-05-22 Daimler Benz Ag Vorrichtung und Verfahren zum Steuern einer selbsttätigen Schaltvorrichtung eines Gangwechselgetriebes eines Kraftfahrzeuges
US5795910A (en) 1994-10-28 1998-08-18 Cor Therapeutics, Inc. Method and compositions for inhibiting protein kinases
US5727726A (en) * 1996-06-14 1998-03-17 Newco Pneumatic Corp. Cassette assembly for a stapling mechanism
AU6678398A (en) 1997-02-27 1998-09-18 Ana Maria Garcia Inhibitors of isoprenyl transferase
GB2323845A (en) 1997-03-31 1998-10-07 Merck & Co Inc MEK inhibiting lactones
EP1140069A1 (en) 1998-12-24 2001-10-10 Novation Pharmaceuticals Inc. COMPOUNDS WHICH AFFECT mRNA STABILITY AND USES THEREFOR
GB9828709D0 (en) 1998-12-24 1999-02-17 Novartis Ag Assay
US6630480B1 (en) * 1999-03-29 2003-10-07 Biochem Pharma Inc. Methods of treating leukemia
WO2001036003A2 (en) 1999-11-15 2001-05-25 Drug Innovation & Design, Inc. Selective cellular targeting: multifunctional delivery vehicles
MXPA02006778A (es) 2000-01-12 2004-04-05 Ventana Inc Metodo para determinar la respuesta a una terapia de cancer.
ES2322888T3 (es) 2000-04-14 2009-07-01 Ventana Medical Systems, Inc. Metodo para la cuantificacion de la expresion de proteina akt.
JP2001294527A (ja) 2000-04-14 2001-10-23 Ajinomoto Co Inc Ｔｈ２反応に特異的な免疫寛容誘導剤
JP2004292315A (ja) 2000-12-14 2004-10-21 Chugai Pharmaceut Co Ltd Ｔａｋ１阻害剤
JP2004292314A (ja) 2000-12-14 2004-10-21 Chugai Pharmaceut Co Ltd ケラチノサイト増殖抑制剤
US7071164B2 (en) 2001-08-16 2006-07-04 Kimberly-Clark Worldwide, Inc. Anti-cancer and wound healing compounds
US7419777B2 (en) 2001-08-21 2008-09-02 Ventana Medical Systems, Inc. Method and quantification assay for determining c-kit/SCF/pAKT status
WO2003056036A2 (en) 2001-12-21 2003-07-10 The Wellcome Trust Genes
US20040096855A1 (en) 2001-12-24 2004-05-20 Michael Stratton Genes
US7915306B2 (en) 2002-03-08 2011-03-29 Eisai Co., Ltd. Macrocyclic compounds useful as pharmaceuticals
NZ535101A (en) * 2002-03-08 2007-07-27 Eisai Co Ltd Macrocyclic compounds useful as pharmaceuticals
EP1663978B1 (en) 2003-07-23 2007-11-28 Bayer Pharmaceuticals Corporation Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
WO2005047542A1 (en) 2003-10-16 2005-05-26 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Treatments for inhibiting development and progression of nevi and melanoma having braf mutations
US20050214325A1 (en) 2004-03-26 2005-09-29 Vvii Newco 2003, Inc. Compositions and methods to increase the effect of a neurotoxin treatment
CA2560269A1 (en) 2004-03-19 2005-09-29 The Penn State Research Foundation Combinatorial methods and compositions for treatment of melanoma
CA2561516A1 (en) 2004-03-30 2005-10-13 Pfizer Products Inc. Combinations of signal transduction inhibitors
WO2005117980A1 (en) 2004-06-04 2005-12-15 Pfizer Products Inc. Method for treating abnormal cell growth
WO2006036941A2 (en) 2004-09-27 2006-04-06 Kosan Biosciences Incorporated Specific kinase inhibitors
US20060216288A1 (en) 2005-03-22 2006-09-28 Amgen Inc Combinations for the treatment of cancer
US7812143B2 (en) 2006-03-31 2010-10-12 Memorial Sloan-Kettering Cancer Center Biomarkers for cancer treatment
EP2182941B1 (en) 2007-07-25 2018-02-28 Eisai R&D Management Co., Ltd. Multikinase inhibitors for use in the treatment of cancer
WO2009058908A2 (en) 2007-10-29 2009-05-07 Eisai R & D Management Co., Ltd. Methods for prognosing the ability of a zearalenone analog compound to treat cancer
JP5492786B2 (ja) 2007-12-07 2014-05-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 ゼラレノンマクロライドアナログを作製するための中間体および方法
US8578879B2 (en) * 2009-07-29 2013-11-12 Applied Materials, Inc. Apparatus for VHF impedance match tuning

Also Published As

Publication number Publication date
KR101721161B1 (ko) 2017-03-29
US20130303489A1 (en) 2013-11-14
US20090082313A1 (en) 2009-03-26
CN101778627B (zh) 2016-04-13
EP2182941A2 (en) 2010-05-12
KR20160123390A (ko) 2016-10-25
US8937056B2 (en) 2015-01-20
CN105748465A (zh) 2016-07-13
WO2009015368A3 (en) 2009-03-26
AU2008279027B8 (en) 2014-03-06
IL247230A (en) 2017-04-30
US8609640B2 (en) 2013-12-17
US20180353468A1 (en) 2018-12-13
IL202307A (en) 2016-08-31
US20150182496A1 (en) 2015-07-02
JP2010534682A (ja) 2010-11-11
KR20150138417A (ko) 2015-12-09
AU2008279027B2 (en) 2014-02-06
AU2008279027A1 (en) 2009-01-29
ES2670423T3 (es) 2018-05-30
WO2009015368A2 (en) 2009-01-29
CA2698271C (en) 2016-07-05
CN101778627A (zh) 2010-07-14
IL202307A0 (en) 2010-06-30
AU2008279027A8 (en) 2014-03-06
KR20100044868A (ko) 2010-04-30
CA2698271A1 (en) 2009-01-29
EP2182941B1 (en) 2018-02-28
US11160783B2 (en) 2021-11-02
KR101573026B1 (ko) 2015-11-30
JP2013189458A (ja) 2013-09-26
JP5484327B2 (ja) 2014-05-07

Similar Documents

Publication Publication Date Title
KR101667960B1 (ko) 암 치료에서 이용하기 위한 멀티키나아제 억제제
US10851073B2 (en) Protein tyrosine phosphatase inhibitors and methods of use thereof
US10954202B2 (en) Protein tyrosine phosphatase inhibitors and methods of use thereof
US20250122160A1 (en) Protein tyrosine phosphatase inhibitors and methods of use thereof
WO2022217042A1 (en) Naphthyl-substituted quinoline-4(1h)-ones and related compounds and their use in treating medical conditions
US20230019236A1 (en) Protein tyrosine phosphatase inhibitors and methods of use thereof
EP2181104B1 (en) Zearalenone macrolide derivatives and uses of the same
EA046190B1 (ru) Новое комбинированное решение для лечения рака, резистентного к химиотерапии
HK1244787A1 (zh) 作为吲哚胺2，3-二加氧酶和/或色氨酸2，3-二加氧酶抑制剂的新颖的5或8-取代的咪唑并[1，5-a]吡啶

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 10